I am director of the Diabetes and Endocrine Disease Translational Research program. This portfolio supports a variety of research relevant to the development of therapies for diabetes, endocrine, and metabolic disorders. This includes research on physiological and pathophysiological processes, molecular structures or biological pathways, and the bioavailability of compounds. Studies in this portfolio examine the ability to selectively modulate the function of drug discovery targets and the ability to translate biological endpoints of preclinical research to the clinic.
The Diabetes Genetics and Genomics program supports research on the genetic and epigenetic variations that influence the effectiveness and safety of pharmacotherapy for diabetes and other disorders of interest. The portfolio promotes efforts to build a strong evidence base for personalized medicine and to translate these and other findings into clinical practice.
My other professional activities include participating in several NIDDK working groups—including ones that focus on type 2 diabetes, obesity, and clinical studies, as well as leading the trans-NIDDK Translational Sciences Working Group.